Skip to content
BUDGET SAVER — Save $50 on every ELISA kit. Limited-time deal.
Lab Essentials Sale — 50% Off Lab Consumables + Free Shipping.
BIG DEAL — 20% Off Transmembrane Proteins.

CTIBIOTECH Joins the eBioHippo Network

ET

eBioHippo Team

Supplier Network

| November 19, 2026 · 7 Human primary cells Patient-derived cancer cells Skin cells Mesenchymal stem cells Immune cells
CTIBIOTECH Joins the eBioHippo Network

CTIBIOTECH human primary cells are now available on eBioHippo. The Lyon-based tissue engineering company supplies single-donor skin cells, mesenchymal stem cells, sorted immune cell subsets and patient-derived cancer cells, all prepared from human tissue donated with informed consent. This launch adds 47 cell products and 6 matched culture media to the eBioHippo catalog, each documented with lot-specific donor information on the Certificate of Analysis.

Who Is CTIBIOTECH?

CTIBIOTECH was founded in 2009 in Meyzieu, near Lyon, France. The company works with human surgical tissue that would otherwise be discarded and turns it into primary cells, tissues and tissue models for biomedical, pharmaceutical and dermato-cosmetic research. Its French laboratory is certified to ISO 9001:2015, and the company reports that its tissues are used in more than 30 countries.

Three activities sit under one roof:

  • Human cell and tissue sourcing. CTIBIOTECH's biobank, Independent Biobank, supplies normal and diseased human tissue, primary cells and culture media. The company describes the biobank as holding more than 50,000 human biological specimens.
  • 3D bioprinted human models. The team bioprints human skin models and patient-derived microtumors. In April 2026 its CTIONCOTEST project received €1.25 million from Bpifrance under the France 2030 program to industrialize bioprinted microtumors made from patients' primary tumor cells (Business Wire, 28 April 2026).
  • Skin and pharmaceutical testing. Through its CTISkin and CTIPharma units, the company runs efficacy and safety studies on human tissue.

In May 2026 the company opened a North American subsidiary, CTIBIOTECH USA, in Philadelphia, Pennsylvania (Business Wire, May 2026). Its scientists have published with academic and industry partners on sebaceous gland models, mesenchymal stem cell sources and 3D bioprinted colorectal cancer models; several of these papers are cited below.

CTIBIOTECH Primary Cells and Media on eBioHippo

The range covers six product families. Every cell product is cryopreserved, stored in liquid nitrogen and shipped on dry ice.

Product family Products What is included
Skin cells 5 Dermal fibroblasts, epidermal keratinocytes, melanocytes, sebocytes and subcutaneous pre-adipocytes
Mesenchymal stem cells 4 Bone marrow, subcutaneous adipose tissue, Wharton's jelly and dental pulp
Adult peripheral blood cells 8 PBMC and immunomagnetically selected CD3+, CD4+, CD8+, CD19+, CD56+, CD25+ and CD14+ cells
Umbilical cord blood cells 10 Mononuclear cells, CD34+ and CD133+ stem/progenitor cells, and the same seven lymphoid and myeloid subsets
Cancer cells and CAFs 20 Breast, ovarian, pancreatic, lung, liver and prostate cancer and lymphoma cells from primary tumors or PDX, plus cancer-associated fibroblasts
Culture media 6 Complete media for fibroblasts, keratinocytes, melanocytes, adipose-derived cells, sebocytes and cancer cells

On a narrow screen, scroll the table sideways to see all three columns.

Browse the full range in the CTIBIOTECH collection, or go straight to CTIBIOTECH cells and CTIBIOTECH culture media.

Patient-Derived Cancer Cells: Primary Tumor and PDX Formats

The oncology range is the largest family in this launch, with 20 products. For several cancer types, CTIBIOTECH offers cells in more than one format, so researchers can match the material to the question:

  • Dissociated primary tumor cells are prepared directly from patient tumor tissue.
  • Dissociated PDX tumor cells are prepared from patient-derived xenograft (PDX) tumors, which are expanded in immunodeficient mice.
  • Characterized tumor cells, from primary tumors or PDX, come with characterization data in the lot data sheet. Data for available lots can be requested before ordering.
  • Cancer-associated fibroblasts (CAFs) from breast, ovarian and liver tumors, and tumoral fibroblasts from prostate cancer, support co-culture models of the tumor stroma.

The choice of format matters. In a study co-authored by CTIBIOTECH scientists, PDX tumors, xenograft-derived organoids and xenograft-derived primary cell cultures were established from the same 20 pancreatic cancer patients. Each model type showed its own transcriptomic phenotype and drug-response profile, and the authors concluded that the models are complementary rather than interchangeable (Hoare et al., Cancers 2021). Tumor origin, donor and clinical data, passage and recommended seeding density are lot-specific and can be requested before you order, so you can confirm that a lot fits your study design.

A dedicated growth medium for cancer cells is available alongside the cells.

Human Skin Cells, Sebocytes and Matched Media

Each skin cell vial comes from a single donor. Human epidermal keratinocytes are offered in three donor age groups (juvenile, adult and aged), and human dermal fibroblasts in four, including donors under one year old. This lets skin-aging and barrier studies compare donors of different ages using cells from the same supplier and the same isolation method. Donor sex, body site and skin phototype are listed on the Certificate of Analysis.

For sebaceous gland research, CTIBIOTECH supplies human sebocytes together with a sebocyte growth and differentiation medium that carries the name Seb4Gln. A medium of that name was developed by CTIBIOTECH and BASF scientists to induce sebocyte proliferation and neutral lipid production, and it supported human sebaceous glands ex vivo for up to 42 days (de Bengy et al., Cell Prolif 2019). The same group later used primary sebocytes in Seb4Gln-optimized medium to model acne-related bacterial colonization (Forraz et al., Microorganisms 2023).

Mesenchymal Stem Cells and Immune Cells

Mesenchymal stem cells (MSCs) are available from four tissue sources: bone marrow, subcutaneous adipose tissue, Wharton's jelly of the umbilical cord, and dental pulp. Source can change how MSCs behave. When MSCs from these four sources were expanded under the same serum-free conditions, they did not differ in viability, clonogenicity or proliferation, but only bone marrow MSCs showed chondrogenic conversion in micromass culture (Fabre et al., Stem Cells Int 2019; CTIBIOTECH co-authors). If your work depends on a particular differentiation outcome, choosing the source deliberately is worth the time.

Immune cells come from two donor groups. Adult peripheral blood cells are from donors aged 18 to 99 years, and cord blood cells from newborns. In both groups, subsets are isolated by density gradient separation followed by immunomagnetic selection. Cord blood CD34+ stem/progenitor cells are offered in two purity grades, Premium (>90% CD34+) and Standard (70–90% CD34+), with the purity of each lot reported on the Certificate of Analysis.

Sourcing, Quality and Documentation

  • Ethical sourcing. Original tissues are obtained with the donor's informed consent, and the company states that it is fully authorized to work with human tissue.
  • Testing. Each product page lists the infectious-disease and microbial testing performed for that product. Lot results are reported on the Certificate of Analysis.
  • Lot-specific data. Donor age, sex and other donor details, passage and cell number are documented per lot.
  • Research use only. CTIBIOTECH cells and tissues are not for use in humans, in animal trials or for diagnostics.

Need a cell type, donor profile or tissue that is not listed? Contact BioHippo and we will check CTIBIOTECH's live inventory for you. You can also read more about the company on the CTIBIOTECH supplier page.

References

  1. Hoare O, Fraunhoffer N, Elkaoutari A, et al. Exploring the complementarity of pancreatic ductal adenocarcinoma preclinical models. Cancers. 2021;13(10):2473. doi:10.3390/cancers13102473
  2. de Bengy AF, Forraz N, Danoux L, et al. Development of new 3D human ex vivo models to study sebaceous gland lipid metabolism and modulations. Cell Prolif. 2019;52(1):e12524. doi:10.1111/cpr.12524
  3. Forraz N, Bize C, Desroches AL, et al. The world's first acne dysbiosis-like model of human 3D ex vivo sebaceous gland colonized with Cutibacterium acnes and Staphylococcus epidermidis. Microorganisms. 2023;11(9):2183. doi:10.3390/microorganisms11092183
  4. Fabre H, Ducret M, Degoul O, et al. Characterization of different sources of human MSCs expanded in serum-free conditions with quantification of chondrogenic induction in 3D. Stem Cells Int. 2019;2019:2186728. doi:10.1155/2019/2186728

Featured Products

Human Epidermal Keratinocytes – Figure 1 of 1
Human Epidermal Keratinocytes
BHC22100002View product →
Human Dermal Fibroblasts – Figure 1 of 1
Human Dermal Fibroblasts
BHC22100001View product →
Human Sebocytes – Figure 1 of 1
Human Sebocytes
BHC22100004View product →
Human Cord Blood CD34+ Stem/Progenitor Cells – Figure 1 of 1
Human Cord Blood CD34+ Stem/Progenitor Cells
BHC22100016View product →
Human Bone Marrow Mesenchymal Stem Cells – Figure 1 of 1
Human Bone Marrow Mesenchymal Stem Cells
BHC22100027View product →
Human Lung Cancer Cells, Characterized, from PDX – Figure 1 of 1
Human Lung Cancer Cells, Characterized, from PDX
BHC22100041View product →
Human Breast Cancer Associated Fibroblasts – Figure 1 of 1
Human Breast Cancer Associated Fibroblasts
BHC22100031View product →
Growth Medium for Cancer Cells – No. 1 medium bottle
Growth Medium for Cancer Cells
BHM22100006View product →
Sebocyte Growth and Differentiation Medium – Figure 1 of 1
Sebocyte Growth and Differentiation Medium
BHM22100005View product →



Related Articles

Vector Biolabs Joins the eBioHippo NetworkMycoFold Joins the eBioHippo Network
Ask a Scientist →